This is a 17-week outpatient study that begins with a screening period. The screening period consists of up to 2 clinic visits over a period of up to 2 weeks. We do not require you to make any changes to your drinking prior to your starting the study medication, but we do require that you have a blood-alcohol level of zero on the first day of screening.
On your first screening visit, you will be asked questions to determine your eligibility.
Once we've determined your eligibility, we'll enroll you into a 12-week study treatment phase. During the study treatment phase, you will receive computer-based alcohol treatment and a nasal spray that is either oxytocin or placebo. Over this 12-week study treatment period, you will be asked to attend 7 in-clinic visits, as well as complete 5 telephone interviews on weeks when you do not have a clinic visit.
You will attend one additional in-clinic visit at the conclusion of the study treatment period. You will also be asked to complete a safety follow-up telephone interview 1-2 weeks after the study treatment period.